PPAR? Antagonist AA452 Triggers Metabolic Reprogramming and Increases Sensitivity to Radiation Therapy in Human Glioblastoma Primary Cells

Autor: Benedetti E., d'Angelo M., Ammazzalorso A., Gravina G.L., Laezza C., Antonosante A., Panella G., Cinque B., Cristiano L., Dhez A.C., Astarita C., Galzio R., Cifone M.G., Ippoliti R., Amoroso R., Di Cesare E., Giordano A., Cimini A.

Publikováno v: Journal of cellular physiology (Online) (2016). doi:10.1002/jcp.25648
info:cnr-pdr/source/autori:Benedetti E.; d'Angelo M.; Ammazzalorso A.; Gravina G.L.; Laezza C.; Antonosante A.; Panella G.; Cinque B.; Cristiano L.; Dhez A.C.; Astarita C.; Galzio R.; Cifone M.G.; Ippoliti R.; Amoroso R.; Di Cesare E.; Giordano A.; Cimini A./titolo:PPAR? Antagonist AA452 Triggers Metabolic Reprogramming and Increases Sensitivity to Radiation Therapy in Human Glioblastoma Primary Cells/doi:10.1002%2Fjcp.25648/rivista:Journal of cellular physiology (Online)/anno:2016/pagina_da:/pagina_a:/intervallo_pagine:/volume

Glioblastoma (GB) is the most common cancer in the brain and with an increasing incidence. Despite major advances in the field, there is no curative therapy for GB to date. Many solid tumors, including GB, experienced metabolic reprogramming in order

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=cnr_________::2396fa58803205bb33c50e97aff85bbd

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.